Lung cancer
Conditions
Interventions
Erector spinae plane nerve block group:Ultrasound-guided erector spinae plane nerve block (20 ml of 0.5% ropivacaine)
Thoracic paravertebral nerve block group:Ultrasound-guided thoracic paravertebral nerve block (0.5% ropivacaine 20 ml)
General anesthesia group:Only general anesthesia is administered
Sponsors
Fujian Cancer Hospital
Eligibility
Sex/Gender
All
Age
25 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age 25-75 years old; 2. Patients undergoing video-assisted thoracoscopic surgery under general anesthesia at the scheduled time; 3. American society of anesthesiologists (ASA) grade I-III; 4.8 kg/m^2<=BMI<=30 kg/m^2; 5. Study participants have a full understanding of the purpose and significance of this trial, voluntarily participate in this clinical trial, and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Emergency or emergency surgery; 2. Those with spinal or spinal cord abnormalities who are not suitable for nerve block anesthesia; 3. Infection at the puncture site; 4. Patients with increased intracranial pressure or central nervous system injury; 5. Have a history of chronic narcotic use or alcohol abuse; 6. Those who are allergic to the components or components of ropivacaine hydrochloride that may be used in the study; 7. Those with a history of allergic diseases in the past, those who have had malignant hyperthermia in the past, and those who have a history of epilepsy in the past; 8. Known significant liver disease (Child-Pugh score B or C or presence of ascites); 9. Renal failure (serum creatinine level >=1.5 mg/dL); 10. Significant cardiac disease (ejection fraction <50%); 11. Overt chronic obstructive pulmonary disease (forced expiratory volume in 1 second or diffusion capacity of carbon monoxide <50% of the predicted value); 12. Subjects with a history of mental illness and cognitive dysfunction; 13. Patients with hematologic diseases, coagulation disorders, or oral warfarin, new anticoagulants such as rivaroxaban and dabigatran due to other diseases; 14. Other conditions judged by the investigator that the subject is not suitable to participate in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postoperative recovery quality;Incidence of postoperative adverse reactions; | — |
Secondary
| Measure | Time frame |
|---|---|
| VAS scores at rest and during coughing;The intraoperative dosage of remifentanil;The number of self-controlled compressions after PCI; | — |
Countries
China
Contacts
Public ContactXuru Zhang
Fujian Cancer Hospital
Outcome results
None listed